Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
基本信息
- 批准号:10341499
- 负责人:
- 金额:$ 34.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:Active SitesAddressAntibodiesBenchmarkingBindingBiological AssayBiological ProcessBiologyCRISPR/Cas technologyCancer PatientCatalytic DomainCell LineCell ProliferationCell physiologyCellsChemicalsChemistryClinicClinicalClinical TrialsCommunitiesComplexDevelopmentEnzymesEvaluationEventExhibitsFDA approvedFelis catusGenetic ModelsGoalsHumanIndividualKnock-outKnowledgeLabelLengthMalignant NeoplasmsMapsMethodologyMethodsModificationMolecularMonitorNoiseOncogenesOncogenicOutcomePTPN11 genePeptidesPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPhenolsPhosphopeptidesPhosphoproteinsPhosphoric Monoester HydrolasesPhosphorylationPhosphorylation SitePhosphotransferasesPhosphotyrosinePhysiologicalPost-Translational Protein ProcessingProtein DephosphorylationProtein Tyrosine KinaseProtein Tyrosine PhosphataseProtein phosphataseProteinsProteomeProteomicsPublicationsRegulationResearchResourcesRoleSensitivity and SpecificitySignal TransductionSiteSpecificitySubstrate SpecificitySulfurSystemTechnologyTestingTherapeuticTranscriptional ActivationTriazolesTyrosineTyrosine PhosphorylationWritinganticancer treatmentbcr-abl Fusion Proteinscell transformationchemical reactionhuman diseaseimprovedinhibitorinnovationinsightinterestnew therapeutic targetnovelpervanadatephosphatase inhibitorphosphoproteomicsprecision medicineprogramsresearch clinical testingsmall moleculesrc Homology Region 2 Domaintherapeutic target
项目摘要
Cells possess enzymes and proteins that can write (kinase), erase (phosphatase), and read (phospho-specific
binding domains) phosphorylation modifications across the proteome to form a complex signaling system for
regulating proliferation, differentiation, and transcriptional activation. Aberrant phosphotyrosine (pTyr) signaling
underlie many human diseases and the identification of molecular components of pTyr processing has
uncovered fundamental principles of signal transduction and furnished new targets for therapy. A key example
is the oncogenic BCR-ABL fusion protein that exhibits constitutive tyrosine kinase activity resulting in excessive
pTyr modifications to transform cells in cancer. The development of small molecule (GleevecTM) and antibody
(HerceptinTM) therapeutics that target pTyr signaling continues to transform anti-cancer treatment options in the
clinic.
Despite enormous clinical potential, a critical barrier that remains in the biomedical field is the ability to
assign site specific phosphorylation events to functional changes for therapeutic targeting in human disease.
Technologies capable of overcoming the low abundance and substoichiometric phosphorylation-site occupancy
of phosphoproteins are needed to address the challenge of functional phosphoproteomic profiling. This is
especially true for phosphorylation of Tyr. Compared with phospho-Ser and -Thr, pTyr modifications represent a
rare subset (~1%) of the human phosphoproteome.
The objective of the proposed studies is to apply a site trapping by covalent probes (dubbed SiteTraP)
methodology to assign substrate specificity to the PTP oncogene, tyrosine-protein phosphatase non-receptor
type 11 (SHP2). The significance of the proposed studies is development of a chemical proteomics strategy to
assign substrate specificity – at the protein and pTyr site level – to individual PTPs directly on native proteins in
lysate and cellular studies.
We will test 2 independent, yet related specific aims directed at benchmarking: (Aim 1) pTyr specificity of
SiteTraP in the presence of phospho-Ser and -Thr in complex proteomes, (Aim 1) Sensitivity of SiteTraP for
capturing SHP2-specific dephosphorylation of pTyr sites in complex proteomes, (Aim 2) Capability of SiteTraP
for capturing global pTyr activation in PTP-disrupted live cells, and (Aim 2) Sensitivity and specificity of SiteTraP
for assigning substrate specificity to SHP2 and determining how SHP2 inhibitors disrupt these networks in live
cells.
Broadly, our proposed studies will be important for the biomedical community by 1) guiding PTP inhibitor
development for targeting specific pTyr modifications in human disease, 2) revealing differences in active site
and allosteric SHP2 inhibitor mode of action for basic and translational understanding of PTP pharmacology,
and 3) gain a deeper understanding of PTP-substrate networks and regulation in live cells.
细胞拥有可以写入(激酶)、擦除(磷酸酶)和读取(磷酸特异性)的酶和蛋白质。
结合结构域)磷酸化修饰,形成复杂的信号系统,
调节增殖、分化和转录激活。异常磷酸酪氨酸(pTyr)信号传导
是许多人类疾病的基础,pTyr加工的分子组分的鉴定
揭示了信号转导的基本原理,为治疗提供了新的靶点。一个重要例子
是一种致癌的BCR-ABL融合蛋白,表现出组成型酪氨酸激酶活性,导致过度的
pTyr修饰以转化癌症细胞。小分子药物(格列卫TM)和抗体的开发
靶向pTyr信号传导的赫赛汀(HerceptinTM)疗法继续改变癌症治疗的选择,
诊所
尽管具有巨大的临床潜力,但生物医学领域仍然存在的一个关键障碍是,
将位点特异性磷酸化事件分配给功能变化,用于人类疾病的治疗靶向。
能够克服低丰度和亚化学计量磷酸化位点占用的技术
磷蛋白的需要,以解决功能磷酸化蛋白质组学分析的挑战。这是
尤其是Tyr的磷酸化。与磷酸化-Ser和-Thr相比,pTyr修饰代表了一种新的修饰方式。
人类磷酸化蛋白质组的罕见子集(~1%)。
拟议研究的目的是通过共价探针(称为SiteTraP)应用位点捕获
PTP癌基因酪氨酸蛋白磷酸酶非受体底物特异性的方法学
11型(SHP 2)。所提出的研究的意义是发展化学蛋白质组学策略,
将底物特异性-在蛋白质和pTyr位点水平-分配给直接在天然蛋白质上的单个PTP,
裂解物和细胞研究。
我们将测试2个独立但相关的针对基准的特定目标:(目标1)
在复杂蛋白质组中存在磷酸化-Ser和-Thr的情况下的SiteTraP,(目的1)SiteTraP对
捕获复杂蛋白质组中pTyr位点的SHP 2特异性去磷酸化,(目的2)SiteTraP的能力
用于捕获PTP破坏的活细胞中的全局pTyr活化,以及(目的2)SiteTraP的灵敏度和特异性
为SHP 2分配底物特异性,并确定SHP 2抑制剂如何破坏这些网络,
细胞
从广义上讲,我们提出的研究将是重要的生物医学界1)指导PTP抑制剂
开发靶向人类疾病中的特异性pTyr修饰,2)揭示活性位点的差异
和变构SHP 2抑制剂的作用模式,用于PTP药理学的基础和转化理解,
和3)获得对活细胞中PTP-底物网络和调节的更深入的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ku-Lung Hsu其他文献
Ku-Lung Hsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ku-Lung Hsu', 18)}}的其他基金
Chemical proteomic investigation of lipid kinase specificity and druggability
脂质激酶特异性和成药性的化学蛋白质组学研究
- 批准号:
10660099 - 财政年份:2023
- 资助金额:
$ 34.37万 - 项目类别:
Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
- 批准号:
10538607 - 财政年份:2022
- 资助金额:
$ 34.37万 - 项目类别:
Defining and targeting substrate specificity of protein tyrosine phosphatases
蛋白质酪氨酸磷酸酶的底物特异性的定义和靶向
- 批准号:
10580475 - 财政年份:2022
- 资助金额:
$ 34.37万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
9398439 - 财政年份:2017
- 资助金额:
$ 34.37万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
10400420 - 财政年份:2017
- 资助金额:
$ 34.37万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
9980632 - 财政年份:2017
- 资助金额:
$ 34.37万 - 项目类别:
Endocannabinoid Biosynthesis in Inflammation and Pain
炎症和疼痛中的内源性大麻素生物合成
- 批准号:
10198879 - 财政年份:2017
- 资助金额:
$ 34.37万 - 项目类别:
Functional Characterization of Diacylglycerol Lipases in Mammalian Physiology
二酰甘油脂肪酶在哺乳动物生理学中的功能表征
- 批准号:
9109601 - 财政年份:2015
- 资助金额:
$ 34.37万 - 项目类别:
Functional Characterization of Diacylglycerol Lipases in Mammalian Physiology
二酰甘油脂肪酶在哺乳动物生理学中的功能表征
- 批准号:
8701001 - 财政年份:2014
- 资助金额:
$ 34.37万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 34.37万 - 项目类别:
Research Grant